LDL
- 抑制剂选择性比较
- 溶解性比较
| 目录号 | 产品目录 | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | 酒精 | ||
| S1655 | Ezetimibe | <1 mg/mL | 81 mg/mL | 81 mg/mL |
| S2748 | Anacetrapib (MK-0859) | <1 mg/mL | 127 mg/mL | 127 mg/mL |
| S7953 | ETC-1002 | <1 mg/mL | 68 mg/mL | <1 mg/mL |
| S2119 | Probucol | <1 mg/mL | 103 mg/mL | 103 mg/mL |
- LDL抑制剂（5）
- 新LDL产品
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1655 |
EzetimibeEzetimibe 是一种有效的、选择性的胆固醇吸收抑制剂，用来降低胆固醇。 |
Caco-2 cells grown in transwell inserts were transfected with scrambled siRNA, or siRNA specific for CCK1R, CCK2R, or both CCK1 and CCK2R and then incubated with 0.002 uCi of [3H]cholesterol micelles in the apical compartment and with culture medium alone (Control) or 10 nm [Thr28,Nle31]CCK with or without 50 uM ezetimibe (EZ) in the basolateral compartment. Absorbed [3H]cholesterol was determined by radioactivity counting of the basolateral medium. Values represent the mean ± S.E. (error bars) of 4-5 independent experiments. *, p < 0.05 versus control; †, p < 0.05 versus cells treated with CCK alone; ‡, p < 0.05 versus cells transfected with scrambled siRNA alone; $, p < 0.05 versus cells treated with scrambled siRNA and CCK.
|
|
| S2748 |
Anacetrapib (MK-0859)Anacetrapib (MK-0859)是一种有效的，选择性，可逆的rhCETP和突变CETP(C13S)抑制剂，IC50分别为7.9 nM和11.8 nM，提高HDL-C，降低LDL-C，不提高醛固酮和血压。Phase 3。 |
||
| S7953 |
ETC-1002ETC-1002是一种可用于口服、降低LDL-C的小分子，是肝脏AMPK的激活剂。 |
||
| S2119 |
ProbucolProbucol 是一种抗高血脂药，通过促进LDL分解代谢率，而降低血液中胆固醇水平。 |
||
| S9187New |
PhillygeninPhillygenin, a bioactive intergradient in Osmanthus fragrans, has anti-inflammatory, anti-obesity and antipyretic activities. It could reduce blood lipid levels and low density lipoprotein. |
